Bianca Weinstock-Guttman presents the 2-year CHORDS study findings showing good outcomes among patients with relapsing-remitting multiple sclerosis receiving ocrelizumab after a suboptimal response to previous disease-modifying therapy (3:17).
Bianca Weinstock-Guttman presents the 2-year CHORDS study findings showing good outcomes among patients with relapsing-remitting multiple sclerosis receiving ocrelizumab after a suboptimal response to previous disease-modifying therapy (3:17).
Don’t fall behind!
Get the latest headlines – in your specialties of choice – delivered straight to your inbox.
medwireNews Bureau Chief
© 2023 Springer Healthcare Limited.
Part of the Springer Nature Group.
